US 11,999,748 B2
Exatecan derivatives, linker-payloads, and conjugates and thereof
Gang Qin, Suzhou (CN); Tony Yantao Zhang, Shanghai (CN); Guangming Chen, Shanghai (CN); Paul H. Song, Suzhou (CN); Boyu Zhong, Shanghai (CN); and Mingyu Hu, Suzhou (CN)
Assigned to GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD., Suzhou (CN)
Filed by GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD., Suzhou (CN)
Filed on Aug. 22, 2023, as Appl. No. 18/453,748.
Application 18/453,748 is a continuation of application No. 18/053,459, filed on Nov. 8, 2022, granted, now 11,814,394.
Claims priority of application No. PCT/CN2021/130896 (WO), filed on Nov. 16, 2021.
Prior Publication US 2024/0018159 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 491/22 (2006.01)
CPC C07D 491/22 (2013.01) 17 Claims
 
1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of formula (i):

OG Complex Work Unit Chemistry
wherein,
a is 0 or 1;
the carbon atoms marked with p1* and p2* each is asymmetric center, and the asymmetric center is S configured, R configured or racemic;
L1 is selected from C1-6 alkylene, which is unsubstituted or substituted with one substituent selected from halogen, —OH and —NH2;
M is —CH2—, —NH— or —O—;
L2 is C1-3 alkylene;
R1 is Cl; and
R2 is F.